Patient Leaflet Updated 07-Oct-2024 | AbbVie Ltd
Skyrizi 150 mg solution for injection in pre-filled pen (Great Britain)
Skyrizi 150 mg solution for injection in pre-filled pen
risankizumab
1. What Skyrizi is and what it is used for
2. What you need to know before you use Skyrizi
3. How to use Skyrizi
4. Possible side effects
5. How to store Skyrizi
6. Contents of the pack and other information
7. Instructions for use
Skyrizi contains the active substance risankizumab.
Skyrizi is used to treat the following inflammatory diseases:
This medicine works by stopping a protein in the body called ‘IL-23’, which causes inflammation.
Plaque psoriasis
Skyrizi is used to treat adults with moderate to severe plaque psoriasis. Skyrizi reduces inflammation and can therefore help reduce symptoms of plaque psoriasis such as burning, itching, pain, redness, and scaling.
Psoriatic arthritis
Skyrizi is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes inflamed joints and psoriasis. If you have active psoriatic arthritis, you may first be given other medicines. If these medicines do not work well enough, you will be given Skyrizi either alone or in combination with other medicines to treat your psoriatic arthritis.
Skyrizi reduces inflammation and can therefore help to reduce pain, stiffness, and swelling in and around your joints, pain and stiffness in your spine, psoriatic skin rash, psoriatic nail damage, and it may slow down damage to the bone and cartilage in your joints. These effects can ease your normal daily activities, reduce tiredness, and improve your quality of life.
Talk to your doctor, pharmacist or nurse before and during the use of Skyrizi:
It is important to keep a record of the batch number of your Skyrizi.
Every time you get a new pack of Skyrizi, note down the date and the batch number (which is on the packaging after “Lot”) and keep this information in a safe place.
Allergic reactions
Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as:
Skyrizi is not recommended for children and adolescents under 18 years of age. This is because Skyrizi has not been studied in this age group.
Tell your doctor, pharmacist or nurse:
If you are not sure, talk to your doctor, pharmacist or nurse before and during the use of Skyrizi.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. This is because it is not known how this medicine will affect the baby.
If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi.
If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.
Skyrizi is not likely to affect your driving and use of machines.
This medicine contains less than 1 mmol sodium (23 mg) per pre-filled pen, that is to say essentially ‘sodium-free’.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
This medicine is given as an injection under your skin (called a ‘subcutaneous injection’).
Each dose is 150 mg given as a single injection. After the first dose, you will have the next dose 4 weeks later, and then every 12 weeks.
You and your doctor, pharmacist or nurse will decide if you should inject this medicine yourself. Do not inject yourself with this medicine unless you have been trained by your doctor, pharmacist or nurse. A caregiver may also give your injection after they have been trained.
Read section 7 ‘Instructions for use’ at the end of this leaflet before injecting Skyrizi yourself.
If you have used more Skyrizi than you should or the dose has been given sooner than prescribed, talk to your doctor.
If you forget to use Skyrizi, inject a dose as soon as you remember. Talk to your doctor if you are not sure what to do.
Do not stop using Skyrizi without talking to your doctor first. If you stop treatment, your symptoms may come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Talk to your doctor or get medical help immediately if you have symptoms of a serious infection such as:
Your doctor will decide if you can keep using Skyrizi.
Tell your doctor, pharmacist or nurse if you get any of the following side effects
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pen label and outer carton after ‘EXP’.
Store in a refrigerator (2°C - 8°C). Do not freeze.
Keep the pre-filled pen in the original carton in order to protect from light.
If needed, you may also store the pre-filled pen out of the refrigerator (up to a maximum of 25°C) for up to 24 hours in the original carton to protect from light.
Do not use this medicine if the liquid is cloudy or contains flakes or large particles.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Skyrizi is a clear and colourless to yellow liquid in a pre-filled pen. The liquid may contain tiny white or clear particles.
Each pack contains 1 pre-filled pen.
This leaflet was last revised in 08/2024
To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder.
Please read all of section 7 before using Skyrizi
STEP 1
Take the carton out of the refrigerator and leave it at room temperature, out of direct sunlight, for 30 to 90 minutes before injecting.
Do not use the pen if liquid has been frozen, even if it has been thawed
STEP 2
Place the following items on a clean, flat surface:
Wash and dry your hands.
STEP 3
Choose from these 3 areas to inject:
Before the injection, wipe where you will inject in a circular motion with an alcohol pad.
Do not inject into areas affected by psoriasis
STEP 4
Hold the pen with the dark grey cap pointing up, as shown.
Check the liquid through the inspection window.
Do not use if the liquid is cloudy or contains flakes or large particles
STEP 5
Hold the pen with your fingers on the grey hand grips.
Turn the pen so that the white needle sleeve points toward the injection site and you can see the green activator button.
Gently squeeze the skin at your injection site to make a raised area and hold it firmly.
Place the white needle sleeve straight (90º angle) against the raised injection site.
STEP 6
Hold the pen so that you can see the green activator button and inspection window.
Push and keep pressing the pen down against the raised injection site.
Press the green activator button and hold the pen for 15 seconds.
STEP 7
Keep pressing the pen down against the injection site.
The injection is complete when:
This takes up to 15 seconds.
STEP 8
When the injection is complete, slowly pull the pen out from the skin.
The white needle sleeve will cover the needle tip and make another “click.”
After completing the injection, place a cotton ball or gauze pad on the skin at the injection site.
Slight bleeding at the injection site is normal
STEP 9
Throw away the used pen in a special disposal container straight after use.
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
www.abbviemedinfo.com
+44 (0)1628 561 092
+44 (0)1628 561 092
www.abbvie.co.uk